Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: the PRODIGE 41 − BEVANEC randomized phase II study
Patients with gastroenteropancreatic (GEP), metastatic or locally advanced, non-resectable, grade 3 poorly-differentiated neuroendocrine carcinoma (NEC) are treated with cisplatin (or carboplatin)-etoposide in first-line palliative chemotherapy (CT1). However, nearly all patients will develop resistance and there is no standard second-line treatment.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Thomas Walter, David Malka, Olivia Hentic, Catherine Lombard-Bohas, Karine Le Malicot, Denis Smith, Aur élie Ferru, Eric Assenat, Guillaume Cadiot, Astrid Lievre, Jean-Emmanuel Kurtz, Laetitia Dahan, Olivier Dubreuil, Vincent Hautefeuille, Céline Lepere Tags: Progress Report Source Type: research
More News: Avastin | Brain | Cancer & Oncology | Carcinoma | Chemotherapy | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Neurology | Palliative | Study | Urology & Nephrology